Case File №
#VI-2026-0672
Risynth Bio
Request Full Data Access to the VendorInvestigator database of peptide tests.
Exhibit I
Compounds on File
32 LINE ITEMS| Compound | Grade | Samples | Mean | Min | Max | Latest |
|---|---|---|---|---|---|---|
| Retatrutide | A Great | 4 | 8.6 | 6.0 | 10.0 | 1 Sep 2025 |
| Tirzepatide | A Great | 4 | 9.5 | 8.4 | 10.0 | 1 Sep 2025 |
| 5-amino-1MQ | X N/A | 1 | 8.5 | 8.5 | 8.5 | 25 Apr 2025 |
| Anavar (Oxandrolone) Raw | X N/A | 1 | 9.6 | 9.6 | 9.6 | 13 Feb 2025 |
| ANPP (4-anilino-N-phenethylpiperidine) CAS 21409-26-7 | X N/A | 1 | 10.0 | 10.0 | 10.0 | 14 Jan 2025 |
| Boldenone Undecylenate (EQ) Raw | X N/A | 1 | 6.2 | 6.2 | 6.2 | 20 Jun 2025 |
| BPC-157 Capsule | X N/A | 1 | 8.2 | 8.2 | 8.2 | 9 Jun 2025 |
| BPC157 10mg + TB500 10mg Blend | X N/A | 1 | 8.6 | 8.6 | 8.6 | 27 Feb 2025 |
| Cerebrolysin | X N/A | 1 | 9.8 | 9.8 | 9.8 | 27 Feb 2025 |
| CJC-1295 With DAC | X N/A | 1 | 9.6 | 9.6 | 9.6 | 28 Mar 2025 |
| CJC-1295 w/o DAC 10mg + IPA 10mg Blend | X N/A | 1 | 8.4 | 8.4 | 8.4 | 2 Jul 2025 |
| CJC-1295 w/o DAC 5mg + IPA 5mg Blend | X N/A | 1 | 10.0 | 10.0 | 10.0 | 16 Mar 2025 |
| Deca (Nandrolone Decanoate) | X N/A | 1 | 6.8 | 6.8 | 6.8 | 16 Mar 2025 |
| DHB (1-Test Cyp) Oral | X N/A | 1 | 9.9 | 9.9 | 9.9 | 9 Jun 2025 |
| Dihexa | X N/A | 1 | 9.9 | 9.9 | 9.9 | 17 Dec 2024 |
| GHK-CU 2000mcg+Glutathione 200mg+Histidine 100mg+Glycine 50mg+NADH 50mg | X N/A | 1 | 8.7 | 8.7 | 8.7 | 2 Apr 2025 |
| GHRP-2 Acetate | X N/A | 1 | 10.0 | 10.0 | 10.0 | 8 Jul 2025 |
| GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | X N/A | 1 | 9.1 | 9.1 | 9.1 | 14 Jan 2025 |
| Hyaluronic acid | X N/A | 1 | 9.8 | 9.8 | 9.8 | 7 May 2025 |
| Immunological Enhancement (Glutathione 200mg+Ascorbic Acid 200mg+Zinc Sulfate 2.5mg) | X N/A | 1 | 9.6 | 9.6 | 9.6 | 6 May 2025 |
| Lipo Mino Mix (B6+Methionine+Inositol+Choline+B1+B2+Carnitine) | X N/A | 1 | 8.5 | 8.5 | 8.5 | 21 May 2025 |
| NA Selank Amidate | X N/A | 1 | 9.7 | 9.7 | 9.7 | 28 Mar 2025 |
| PMK methyl glycidate CAS 1369021-80-6 | X N/A | 1 | 9.3 | 9.3 | 9.3 | 16 Mar 2025 |
| Primobolan Oral (Methenolone Acetate) | X N/A | 1 | 8.6 | 8.6 | 8.6 | 16 Mar 2025 |
| Retatrutide 5mg + Cagrilintide 5mg Blend | X N/A | 1 | 9.2 | 9.2 | 9.2 | 3 Jul 2025 |
| Selank | X N/A | 1 | 10.0 | 10.0 | 10.0 | 24 Apr 2025 |
| SNAP-8 | X N/A | 1 | 9.8 | 9.8 | 9.8 | 3 Jun 2025 |
| Stanozolol (Winstrol) Raw | X N/A | 1 | 7.1 | 7.1 | 7.1 | 11 Jun 2025 |
| Tesofensine | X N/A | 1 | 10.0 | 10.0 | 10.0 | 13 Jun 2025 |
| Test Enanthate | X N/A | 1 | 9.6 | 9.6 | 9.6 | 27 Feb 2025 |
| Test Suspension | X N/A | 1 | 10.0 | 10.0 | 10.0 | 20 Jun 2025 |
| Vilon | X N/A | 1 | 6.8 | 6.8 | 6.8 | 27 Feb 2025 |
Exhibit II
Evidence Log
37 LABORATORY RETURNS| Filed | Compound | Score | Claimed | Found | Δ Qty | Purity | Batch № | Lab | Source |
|---|---|---|---|---|---|---|---|---|---|
| 25 May 2026 | Boldenone Undecylenate (EQ) Raw | 7.0 A | 100g | 102.4g | +2.4% | 97.38% | av99pt | Lab A | Community |
| 24 May 2026 | Stanozolol (Winstrol) Raw | 8.6 A | 1g | 0.9g | -9.0% | 98.62% | l5udod | Lab E | Public |
| 24 May 2026 | BPC157 10mg + TB500 10mg Blend | 9.8 A | 2mg | 2.1mg | +3.7% | 95.24% | r2y1dy | Lab F | Community |
| 24 May 2026 | Cerebrolysin | 10.0 A | 5mg | 4.5mg | -10.6% | 99.00% | zwy1qp | Lab B | Public |
| 24 May 2026 | CJC-1295 With DAC | 10.0 A | 10mg | 8.7mg | -12.6% | 99.96% | ntbs25 | Lab B | Community |
| 24 May 2026 | Deca (Nandrolone Decanoate) | 4.4 C | 250mg/ml | 234.9mg/ml | -6.0% | 99.24% | isr64o | Lab F | Community |
| 24 May 2026 | PMK methyl glycidate CAS 1369021-80-6 | 10.0 A | 100g | 98.0g | -2.0% | 98.15% | mn1yu1 | Lab C | Public |
| 23 May 2026 | DHB (1-Test Cyp) Oral | 10.0 A | 50mg | 52.3mg | +4.6% | 97.13% | peasqa | Lab A | Community |
| 21 May 2026 | GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | 9.4 A | 10mg | 12.1mg | +20.9% | 96.96% | jl69ms | Lab B | Public |
| 19 May 2026 | Primobolan Oral (Methenolone Acetate) | 9.9 A | 50mg | 46.0mg | -8.1% | 96.26% | yi0yw9 | Lab E | Community |
| 17 May 2026 | ANPP (4-anilino-N-phenethylpiperidine) CAS 21409-26-7 | 10.0 A | 500g | 438.1g | -12.4% | 96.24% | 3c9b4c | Lab G | Community |
| 29 Jan 2026 | CJC-1295 w/o DAC 10mg + IPA 10mg Blend | 8.6 A | 15mg | 17.4mg | +15.7% | 98.16% | csw5yc | Lab G | Public |
| 29 Jan 2026 | CJC-1295 w/o DAC 5mg + IPA 5mg Blend | 10.0 A | 50mg | 56.9mg | +13.7% | 98.29% | 1t1m9f | Lab D | Community |
| 26 Jan 2026 | Hyaluronic acid | 9.8 A | 10mg | 9.2mg | -8.2% | 98.33% | b42z9n | Lab E | Public |
| 19 Jan 2026 | Anavar (Oxandrolone) Raw | 9.6 A | 10g | 10.5g | +5.1% | 98.26% | v8dcdo | Lab B | Public |
| 19 Jan 2026 | BPC-157 Capsule | 7.7 A | 100mg | 111.3mg | +11.3% | 98.24% | 4l69i4 | Lab G | Public |
| 7 Jan 2026 | 5-amino-1MQ | 6.5 A | 10mg | 8.9mg | -10.6% | 97.72% | necoog | Lab D | Public |
| 12 Dec 2025 | SNAP-8 | 10.0 A | 5mg | 5.1mg | +1.1% | 99.97% | 17fcm8 | Lab C | Community |
| 23 Nov 2025 | Dihexa | 9.7 A | 20mg | 23.3mg | +16.4% | 96.67% | qvvnco | Lab A | Community |
| 17 Nov 2025 | Immunological Enhancement (Glutathione 200mg+Ascorbic Acid 200mg+Zinc Sulfate 2.5mg) | 9.0 A | 250mg/ml | 229.3mg/ml | -8.3% | 97.22% | hodh8d | Lab C | Public |
| 17 Nov 2025 | Lipo Mino Mix (B6+Methionine+Inositol+Choline+B1+B2+Carnitine) | 10.0 A | 300mg/ml | 266.5mg/ml | -11.2% | 96.09% | hsrr93 | Lab A | Community |
| 17 Nov 2025 | Retatrutide 5mg + Cagrilintide 5mg Blend | 7.9 A | 5mg | 6.1mg | +22.8% | 95.46% | r8hthx | Lab C | Community |
| 17 Nov 2025 | Selank | 10.0 A | 15mg | 18.7mg | +24.5% | 96.71% | o4pcib | Lab D | Public |
| 5 Nov 2025 | Tesofensine | 9.6 A | 50mg | 61.0mg | +22.0% | 95.96% | bonmj4 | Lab D | Community |
| 4 Nov 2025 | NA Selank Amidate | 8.5 A | 20mg | 19.8mg | -0.9% | 98.14% | tcs97l | Lab B | Public |
| 9 Oct 2025 | GHK-CU 2000mcg+Glutathione 200mg+Histidine 100mg+Glycine 50mg+NADH 50mg | 8.9 A | 200mg/ml | 173.2mg/ml | -13.4% | 95.16% | 1gez4s | Lab G | Community |
| 9 Oct 2025 | GHRP-2 Acetate | 10.0 A | 5mg | 6.2mg | +24.8% | 98.10% | waooya | Lab F | Public |
| 9 Oct 2025 | Test Enanthate | 8.3 A | 100mg/ml | 100.3mg/ml | +0.3% | 99.96% | m2uggz | Lab B | Public |
| 9 Oct 2025 | Test Suspension | 9.1 A | 200mg/ml | 185.0mg/ml | -7.5% | 96.41% | gn0i28 | Lab E | Community |
| 9 Oct 2025 | Vilon | 5.8 B | 2mg | 1.9mg | -3.6% | 97.29% | k25aac | Lab F | Public |
| 4 Sep 2025 | Tirzepatide | 9.8 A | 30mg | 28.3mg | -5.7% | 99.95% | 2025/6-7-15-TZ | Lab E | Public |
| 4 Sep 2025 | Tirzepatide | 10.0 A | 40mg | 38.9mg | -2.8% | 99.93% | 2025/6-7-15-TZ | Lab E | Public |
| 4 Sep 2025 | Retatrutide | 10.0 A | 5mg | 4.8mg | -4.0% | 99.95% | 2025/6-7-15-RT | Lab E | Public |
| 4 Sep 2025 | Retatrutide | 9.8 A | 20mg | 19.5mg | -2.5% | 99.83% | 2025/6-7-15 | Lab E | Public |
| 4 Sep 2025 | Tirzepatide | 10.0 A | 10mg | 9.75mg | -2.5% | 99.90% | 2025/6-715-tz | Lab E | Public |
| 1 Sep 2025 | Tirzepatide | 8.4 A | 20mg | 22.07mg | +10.3% | 99.93% | 2025/6-7-15-TZ | Lab A | Public |
| 1 Sep 2025 | Retatrutide | 6.0 B | 10mg | 11.12mg | +11.2% | 98.83% | 2025/6-7-15R | Lab A | Public |
— END OF EVIDENCE LOG —